Abstract
There has been tremendous progress in the identification of molecular and cellular markers that may predict the tendency for disease progression in patients with chronic lymphocytic leukemia (CLL) or detect minimal residual disease after therapy. These developments have created some uncertainty for clinicians with regard to the optimal incorporation of these novel markers into the daily management of CLL patients. Therefore, this article will attempt to summarize the current evidence with regard to novel biological markers in CLL. The recommendations of the recently revised National Cancer Institute guidelines for the diagnosis and treatment of CLL as reported by the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) [1] will be incorporated.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
